Abstract submission is now open. The approved abstracts will be published in a collection in the regular issue of Human Gene Therapy(HGT) . We warmly welcome rare diseases researchers to submit abstracts!
HGT is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes important advances in DNA, RNA, cell and immune therapies, validating the latest advances in research and new technologies. HGT has an Impact Factor of 4.2.
Established in 1990, HGT provides a prestigious forum for publishing scientific and clinical research, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.
The abstract submission guidelines are as follows:
All abstracts must be written in English, and the abstract text should not exceed 250 words.
Please follow the format outlined in the attached template, which includes the title, author(s), affiliation(s), corresponding author's email, abstract text, and keywords.
The abstract cannot contain graphs or tables.
Authors are responsible for the accuracy of their content. Submissions that do not comply with the format or contain inaccuracies will not be accepted.
Abstract submission topics includes:
Basic and clinical advances in gene therapy
Delivery systems
Cell therapy
Immunotherapy
Clinical genome editing
Small nucleic acid therapeutics, including RNAi
Clinical trials (including confirmatory or negative results)
Improvements in vector developments
Animal models
Pre-clinical animal/in vitro studies to assess safety of gene and cell therapy products
Clinical protocols
Commercial development of gene and cell therapy products
Abstract Submission Deadline: April 18, 2024.
Notification of Accepted Abstracts: By April 26, 2024.
Abstract Template attached:
Abstract Template for GRDRS2024.pdf
Abstract Submission: Please complete the abstract according to the template, then submit it by clicking on the link http://lxi.me/xh5hs or scanning the QR code below (via computer/mobile).
即日起，大会开启摘要投稿，审核通过的摘要将以合辑形式发表在Human Gene Therapy（HGT）的正刊中，摘要作者可来到大会现场以壁报方式分享自己的研究，欢迎罕见病科研工作者踊跃投稿。
HGT是涵盖基因疗法各个方面的最重要的多学科期刊，刊登DNA、RNA、细胞和免疫疗法的重要进展，并验证研究和新技术的最新进展。该期刊的影响因子为4.2。
HGT创刊于1990年，为发表科学和临床研究成果（包括伦理、法规、监管、社会和商业议题）提供了一个享有盛誉的平台，推动治疗程序的发展和进步，改善患者的治疗效果，并最终治愈疾病。
摘要要求：
· 摘要全部使用英语，摘要正文不超过250单词。
· 摘要格式请参照附件模板，包含标题、作者、作者单位、通讯作者邮箱、摘要正文、关键词。
· 摘要不能包含任何图表。
· 文责自负，如格式不符合要求或信息有误，将不予录用。
摘要投稿主题：
· 基因治疗的基础和临床进展
· 递送系统
· 细胞疗法
· 免疫疗法
· 临床基因组编辑
· 小核酸疗法（包括RNAi）
· 临床试验（包括确证或阴性结果）
· 载体开发的改进
· 动物模型
· 评估基因和细胞疗法产品安全性的动物/体外临床前研究
· 临床方案
· 基因和细胞治疗产品的商业开发
摘要提交截止时间：2024年4月18日
录用稿件通知时间：2024年4月26日之前
摘要模版附件：
Abstract Template for GRDRS2024.pdf
提交摘要：请根据模板完成摘要，并点击链接http://lxi.me/xh5hs或扫描下方二维码提交（电脑/手机均可）。
